% | $
Quotes you view appear here for quick access.

Anika Therapeutics, Inc. (ANIK) Message Board

  • algo41 algo41 Feb 28, 2013 11:24 AM Flag

    Were products developed in house?

    I am a potential new investor. Did Anika develop all their products in house? Are they making most of their revenue from one product? Stock sure seems cheap, so only possible negative I can think of is longer term revenue.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • yes and yes---remember the management is still there.

      • 2 Replies to rancholasuvas
      • retiredladyinsouthflorida retiredladyinsouthflorida Feb 28, 2013 5:24 PM Flag

        (see below before reading this ) -- One more thing -- I personally hope that JNJ will eventually buy them out. I suspect other investors feel the same way. Anika is too small to be able to attract the kind of management team they need in order to succeed on their own. It's as simple as that. But Orthovisc is a great moneymaker for JNJ, and Monovisc will be, too, if they ever get their act together with respect to how they present it to the FDA. And the eyeball stuff is also best-in-class and, until Orthovisc took off, that was how they made their money. Their partnership with Bausch&Lomb goes back as long as their existence, but B&L is itself a bit of a mess right now and has been for a couple of years or so now. They are trying to market the eyeball product to other distributors, but ... And in case you're wondering about this eyeball stuff,. it's used in lens-replacement surgeries so it's important stuff that lots of eye doctors use routinely.

      • retiredladyinsouthflorida retiredladyinsouthflorida Feb 28, 2013 5:15 PM Flag

        Rancholasuvas -- your reply is not helpful to a novice. Let me explain to Algo41. Hello Algo41 -- I've held Anika stock since it split off from Medchem, which I owned then, more than 20 yrs ago (Medchem was bought out by Bard), so my perspective is a bit different (!) from the traders who post on this message board. Some of the stuff they make was developed when they were a subsidiary of Medchem; those include the hyaluronate product used in eyeball surgery (it's changed names at least once because it's always been marketed through others, notably Bausch&Lomb, but that's a long convoluted story in itself) and also the Orthovisc product used as a viscosupplement for early to mid-stage osteoarthritic knees. After the spinoff, they developed an hyaluronate-based dermal filler product (cosmetic surgery, to eliminate wrinkles) which has been marketed in both the US & Europe, but which has also changed names at least twice due to a star-crossed marketing history that began with L'Oreal & ended (at least until now) with a marketing partner that went belly-up for reasons totally unrelated to the Anika product (but the story reflects badly on management's judgement in marketing partners). They then purchased proprietary technology from an Italian company, FidiaAB, but as far as I'm concerned the deal they made was much more in FidiaFAB's best interest than in Anika's, plus Anika simply didn't have what it took to manage the Italian facility so it was a big mess, which they dismantled recently to cut losses (but they still own the patent rights which are scientifically strong). Monovisc is Anika's, a good product, but the FDA approval was badly managed so it's doing great in Europe but is not available in the US. Hence rancho's remark about management. Thank Gd for JNJ.

43.99+0.34(+0.78%)Oct 24 4:00 PMEDT